- Home
- GNPX vs SEED Comparison
GNPX vs SEED Comparison
Compare GNPX & SEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- SEED
- Stock Information
- Founded
- GNPX 2009
- SEED 1997
- Country
- GNPX United States
- SEED China
- Employees
- GNPX N/A
- SEED N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- SEED Farming/Seeds/Milling
- Sector
- GNPX Health Care
- SEED Consumer Staples
- Exchange
- GNPX Nasdaq
- SEED Nasdaq
- Market Cap
- GNPX 6.6M
- SEED 7.5M
- IPO Year
- GNPX 2018
- SEED N/A
- Fundamental
- Price
- GNPX $0.28
- SEED $0.92
- Analyst Decision
- GNPX
- SEED
- Analyst Count
- GNPX 0
- SEED 0
- Target Price
- GNPX N/A
- SEED N/A
- AVG Volume (30 Days)
- GNPX 3.4M
- SEED 82.4K
- Earning Date
- GNPX 08-08-2025
- SEED 06-26-2025
- Dividend Yield
- GNPX N/A
- SEED N/A
- EPS Growth
- GNPX N/A
- SEED N/A
- EPS
- GNPX N/A
- SEED N/A
- Revenue
- GNPX N/A
- SEED $12,910,081.00
- Revenue This Year
- GNPX N/A
- SEED N/A
- Revenue Next Year
- GNPX N/A
- SEED N/A
- P/E Ratio
- GNPX N/A
- SEED N/A
- Revenue Growth
- GNPX N/A
- SEED N/A
- 52 Week Low
- GNPX $0.20
- SEED $0.74
- 52 Week High
- GNPX $3.97
- SEED $4.80
- Technical
- Relative Strength Index (RSI)
- GNPX 55.29
- SEED 35.52
- Support Level
- GNPX $0.25
- SEED $0.74
- Resistance Level
- GNPX $0.27
- SEED $1.03
- Average True Range (ATR)
- GNPX 0.03
- SEED 0.12
- MACD
- GNPX 0.00
- SEED -0.01
- Stochastic Oscillator
- GNPX 90.71
- SEED 20.94
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.